Abeona Therapeutics (LTS:0H7R) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0H7R Abeona Therapeutics Inc LTS:0H7R
31 GF Score
Price $5.96
! 5 Warning Signs
View Full Analysis

What is Abeona Therapeutics Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

LTS:0H7R
31GF Score
Abeona Therapeutics Inc LTS:0H7R
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abeona Therapeutics Business Description

Other Exchanges ABEO:USAPCJ:Germany
Address 6555 Carnegie Avenue, 4th Floor, Cleveland, OH, USA, 44103
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
31GF Score

Get the complete analysis for LTS:0H7R

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.96
Price